<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="167080">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00922480</url>
  </required_header>
  <id_info>
    <org_study_id>A657-BR-CT-301</org_study_id>
    <nct_id>NCT00922480</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Hypertension Patients</brief_title>
  <official_title>A Randomized, Double-blind, Losartan-controlled, Parallel Group Comparison Dose Titration Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan 60mg~120mg in Patients With Mild to Moderate Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kangbuk Samsung Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Konkuk University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Konyang University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Keimyung University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University Guro Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dongguk University International Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ajou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wonju Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yeungnam University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inha University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cheil General Hospital and Women’s Healthcare Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chungnam National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chungbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hanyang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the antihypertensive efficacy and safety of
      Fimasartan (BR-A-657•K) 60 mg~120 mg in patients with mild to moderate essential
      hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fimasartan (BR-A-657-K), a selective blocker of AT1 receptor subtype, showed the rapid and
      potent antihypertensive effect in many hypertensive models. Phase I study, Fimasartan
      (BR-A-657-K) 20mg ~ 480mg single dosing with healthy subjects, demonstrated that the
      Fimasartan(BR-A-657-K) was very safe and well tolerated. Another phase I study, Fimasartan
      (BR-A-657-K) 120mg and 360mg dosing for 7 days, also showed that Fimasartan (BR-A-657-K) was
      safe and tolerable though one temporal adverse event was observed in high dose.

      A Randomized, Double-blind, Losartan-controlled, Parallel Group Comparison Dose Titration
      Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan
      (BR-A-657•K) 60mg~120mg in Patients with Mild to Moderate Essential Hypertension.

      Approximately 480 patients will be enrolled over 12 months in 24 centers nationwide.

      After 2 weeks of placebo run-in period, all subjects will be randomized into one of the
      following 2 groups. Subjects will take test/control drug for 12 weeks of treatment period.
      And Extensin study have 12 weeks in treatment period.

      If subjects take any antihypertensive medications before screening, the subjects will have 1
      week of wash-out period.

      If the hypertension is not controlled well, there is a possibility of dose titration.

      Group I : Fimasartan group. Group II : Losartan group
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>12 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>4 week, 8 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">506</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Losartan group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fimasartan 60mg, 120mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan</intervention_name>
    <description>Fimasartan 60 ~ 120mg/po take one tablets once a day</description>
    <arm_group_label>1</arm_group_label>
    <other_name>A657-BR-CT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan (Control)</intervention_name>
    <description>Losartan 50 mg ~ 100 mg/po, take one tablets once a day</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Cozar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mild to moderate essential hypertension : sitting diastolic blood pressure measured
             at Placebo visit and Baseline are 90~109mmHg inclusive and the difference between
             sitting diastolic blood pressures measured at Placebo visit and Baseline(Day0) is
             under 7mmHg.

          -  Subjects who agree to participate in this sudy and give written informed consent

          -  Subjects considered to understand the study, be cooperative, and able to be
             followed-up until the end of the study

        Exclusion Criteria:

          -  The sitting DBP is less than 89mmHg or more than 110mmHg or severe hypertensive
             patient with sitting systolic blood pressure over 200mmHg Patients with secondary
             hypertension

          -  Patients with severe renal(Creatinine more 1.5 times than upper limit of normal),
             gastrointestinal, hematological or hepatic(AST, ALT more 2 twice more than upper
             limit of normal)disease etc. which might affect absorption, disposition, metabolism
             or excretion of the drug

          -  Patients with postural hypotension

          -  Patients with sever insulin dependent diabetes mellitus or uncontrolled diabetes
             mellitus(HbA1c&gt;9%, regimen change of oral hypoglycemic agents within 12weeks, treated
             insulin before screening)

          -  Patients with a history of myocardial infarction, severe coronary artery disease or
             clinically significant heart failure or valvular defect in last 6 months

          -  Patients with consumptive disease, autoimmune disease, connective tissue disease

          -  Patients with a history of type B or C hepatitis(include carrier)

          -  Patients with HIV or hepatitis

          -  Patients with clinically significant laboratory abnormality

          -  Patients receiving any drugs known to affect blood pressure or medical treatments
             that can influence the blood pressure

          -  Patients with allergy or contraindication to any angiotensin II receptor antagonists

          -  Female of childbearing potential who does not undergo hysterectomy or is not
             post-menopausal

          -  Patients judged to have a history of alcohol or drug abuse by the investigator

          -  Patients participated other clinical trial 12 weeks before Screening Patients judged
             to be inappropriate for this study by the investigator with other reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Byung-Hee Oh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 31, 2016</lastchanged_date>
  <firstreceived_date>June 16, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Losartan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antihypertensive Agents</mesh_term>
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
